NCT02516241 2026-04-20
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT02365597 2026-04-13
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT03390504 2026-04-13
THOR
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05645692 2026-01-30
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04223856 2025-06-13
EV-302
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03425201 2024-12-31
NICARAGUA
Fundacion CRIS de InvestigaciĆ³n para Vencer el CĆ”ncer
Phase 1/2 Completed
NCT02891161 2024-11-27
DUART
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT02033993 2023-08-22
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
Canadian Cancer Trials Group
Phase 2 Completed
NCT04131634 2021-06-16
SAbR
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00790426 2020-12-19
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
Novartis
Phase 2 Completed
NCT02880345 2019-04-23
RADVAXā¢: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT00821327 2016-10-25
Gemzar, Cisp, Sunitinib Urothelial Ca
US Oncology Research
Phase 2 Completed
NCT01801137 2016-06-21
AFINIVEST
Hopital Foch
Phase 2 Completed